(Press-News.org) In a new study of more than 40,000 patients, researchers at Intermountain Health in Salt Lake City have found that patients who have no evidence of calcium in their coronary arteries are not only significantly less likely to die from heart conditions – including heart attacks and heart failure– but also are at reduced risk of death from non-cardiac medical conditions.
Coronary artery calcium (CAC) is a strong predictor of how likely someone is to develop clinical coronary artery disease. It is an excellent measure of coronary plaque burden.
When cholesterol-laden plaque builds up in the coronary arteries, blood flow to heart muscle is limited, and plaque rupture with coronary thrombosis can block off blood flow completely, leading to unstable angina or a heart attack.
As plaques age, they attract calcium, which can be imaged with computed tomography. If someone has a coronary artery calcium (CAC) score of zero, the chance that their coronary arteries are clear of advanced plaques is very high. If CAC is present, then their risk of a future heart attack is much greater and in proportion to the CAC score.
In the Intermountain Health study, researchers found that patients with any level of coronary artery calcium have more than two times greater risk of dying of any medical condition than patients with no evidence of CAC – including medical conditions not related to heart health.
“We know that not having any coronary artery calcium is a predictor of being in good coronary health, but we were surprised to find that it may also be a sign you’re in good general health,” said Jeffrey L. Anderson, MD, distinguished clinical and research physician at Intermountain Health and principal investigator of the study.
“Someone’s coronary artery calcium score could be a more powerful predictor of a person’s overall health than we previously thought. We don’t know the mechanism for this extended benefit, but coronary plaque may be correlated with plaque in blood vessels in other parts of the body, and having atherosclerosis may also negatively impact immune surveillance, an important protective mechanism against cancer.”
Findings from the study were presented at the American Heart Association Scientific Sessions 2025 in New Orleans on Saturday, Nov. 8.
In the large, retrospective study, Intermountain researchers reviewed the medical records of 40,018 Intermountain Health patients, whose doctors determined they were at risk of having or developing heart disease, and as part of that care, underwent a PET/CT stress test.
Of the patients in the study, 7,967 had no evidence of coronary artery calcium, and 32,051 had some levels of CAC. Researchers then followed up with patients for five years and reviewed all-cause mortality of people with a CAC score of zero compared to those with a CAC score of greater than zero.
Researchers found that people who had any level of coronary artery calcium were 2 to 3 times more likely to have died than those without CAC in those five years.
Even more surprising, of those with CAC who died, only about one quarter did so from cardiovascular disease. That means most of these patients died of something else, i.e., non-cardiovascular diseases.
Researchers say they’re not sure why patients’ all-cause mortality rates were higher for those with evidence of coronary artery calcium. The next step in this research, they say, is to examine those non-cardiovascular deaths, and better stratify the causes behind them.
“This may help uncover the mechanism of why a coronary artery calcium score predicts death due to non-coronary artery problems,” said Dr. Anderson. “It’s not clear to us right now, and it requires more study, but it’s a very interesting observation and suggests that coronary artery calcium has prognostic value beyond just heart attacks and other heart -related causes.”
###
END
Coronary artery calcium (CAC) CT scans are becoming a more commonly used tool to effectively determine a patient’s future risk of heart disease and heart attack.
These minimally invasive scans measure how much calcium is already present in the arteries of the heart, so that clinicians can determine if a patient needs medical intervention or other preventative measures, including statin medications.
Now an important new study from heart researchers at Intermountain Health in Salt Lake City ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria (excess albumin in the urine) and the risk of chronic kidney disease (CKD) progression, and certain mineralocorticoid receptor antagonists have similar effects in people with type 2 diabetes and CKD. Investigators recently assessed the albuminuria-lowering efficacy and safety of the novel mineralocorticoid receptor antagonist balcinrenone combined with the SGLT2 dapagliflozin. In the double-blind, active-controlled clinical trial, both doses of this novel balcinrenone/dapagliflozin combination outperformed dapagliflozin alone, cutting levels of ...
Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients’ treatment significantly reduced the risk of major adverse cardiovascular events in those who are at high risk. Results were presented today at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
“The results of this trial offer hope for preventing a first heart attack, stroke, or other ...
Researchers from Mass General Brigham have found that olezarsen—a drug designed to lower triglyceride levels—can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels. The results, from two randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b), were presented at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
Severe hypertriglyceridemia is a condition in which the level of triglycerides (a type of fat that circulates in the blood) is very high. Approximately 1 in 100 people in the U.S. have severe hypertriglyceridemia. ...
Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology. Globally, the prevalence of MASLD is estimated even over 30%, affecting over one-third of adults. Parallelly, alcohol remains a major risk factor, with heavy drinking contributing to 90–95% of SLD cases and up to 10% advancing to cancer.
Genetic ...
About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure.
Corresponding Authors: To contact the corresponding authors, email Brendon L. Neuen, PhD (bneuen@georgeinstitute.org.au) and Hiddo J. L. Heerspink, PhD (h.j.lambers.heerspink@umcg.nl).
To access the embargoed study: Visit our For The ...
In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists’ Consortium (SMART-C), led by The George Institute for Global Health.
SGLT2 inhibitors, originally developed to treat type 2 diabetes, have since demonstrated substantial protection against heart failure and chronic ...
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by starting HIV medication immediately after infection – i.e. within a few days. They saw that six months after this early treatment, the immune system did indeed work as in people without HIV. But in the longer term, the immune system was disrupted again. This is shown by research by Amsterdam UMC, published in the journal EBioMedicine.
Early treatment protects immune systems only temporarily
For this study, the scientists examined ...
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide.
Led by researchers at NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, the analysis explored the rise of the illness, in which the kidneys gradually lose their ability to filter waste and excess fluid from the blood. Mild cases may have no symptoms while the most severe stages ...
In 2023, chronic kidney disease (CKD) was the 9th-leading cause of death worldwide, responsible for nearly 1.5 million deaths.
Unlike most other leading causes of death, CKD mortality rates continue to rise, signaling a growing global health crisis.
In 2023, CKD ranked as the 12th-leading cause of disability worldwide and the 7th-leading driver of cardiovascular deaths. Kidney dysfunction alone accounted for almost 12% of all global cardiovascular deaths.
Diabetes, obesity, and high blood pressure remain the top drivers of CKD, alongside dietary risks and environmental factors.
SEATTLE, Wash. – Nov. 7, ...
